Cambridge Investment Research Advisors
VAXX

Cambridge Investment Research Advisors’s Vaxxinity, Inc. Class A Common Stock VAXX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio VAXX Stock Details VAXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-12,000
Closed -$9K – 3469
2024
Q1 		$9K Hold
12,000
– – ﹤0.01% 3292
2023
Q4 		$10K Hold
12,000
– – ﹤0.01% 3168
2023
Q3 		$16K Sell
12,000
-11
-0.1% -$24 ﹤0.01% 3095
2023
Q2 		$30K Buy
12,011
+11
+0.1% +$23 ﹤0.01% 3111
2023
Q1 		$27K Hold
12,000
– – ﹤0.01% 3086
2022
Q4 		$17K Buy
+12,000
New +$20.2K ﹤0.01% 3055

Other funds holding VAXX

SWM
Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
RF
Robinswood Financial Kirkland, Washington $349M AUM 14.9% 1-Year Est. Return

Cambridge Investment Research Advisors's VAXX Position: Q2 2024 in Review

Cambridge Investment Research Advisors sold out of Vaxxinity, Inc. Class A Common Stock (VAXX) in Q2 2024, closing a stake of 12,000 shares — an estimated $9K sold.

Cambridge Investment Research Advisors first reported a position in VAXX in Q4 2022 and held it in 6 quarters. The position peaked at $30K in Q2 2023. 8 funds tracked by Wall St. Rank hold VAXX as of Q2 2024.

  • Cambridge Investment Research Advisors reported no remaining Vaxxinity, Inc. Class A Common Stock position as of Q2 2024 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 12,000 Vaxxinity, Inc. Class A Common Stock shares in Q2 2024, an estimated $9K.
  • Cambridge Investment Research Advisors first reported a position in Vaxxinity, Inc. Class A Common Stock in Q4 2022 and held it in 6 quarters.
  • Cambridge Investment Research Advisors's Vaxxinity, Inc. Class A Common Stock position peaked at $30K in Q2 2023.
  • 8 funds tracked by Wall St. Rank held Vaxxinity, Inc. Class A Common Stock as of Q2 2024.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2024, filed 26 Jul 2024.